Status:
COMPLETED
Additional GLP-1 Analogue on CSII Treatment for Poorly Controlled Type 2 Diabetic Patients
Lead Sponsor:
Chang Gung Memorial Hospital
Conditions:
Type 2 Diabetes Mellitus
Eligibility:
All Genders
20-80 years
Phase:
NA
Brief Summary
Background: Continuous subcutaneous insulin infusion (CSII) has been demonstrated to be an effective clinical tool for intensive insulin therapy in Type 1 diabetic patients. Type 2 diabetes patients h...
Detailed Description
In the poorly controlled type 2 DM, insulin therapy is the treatment of choice to make sugar on target. Actually, however, the general control rate is not good and partially due to the complex etiolog...
Eligibility Criteria
Inclusion
- Age \> 20 years old
- DM diagnosed \> 2 years
- HbA1c level of 8% to 12%
- Receiving insulin premixed insulin twice daily and total insulin daily dose \> 0.6 u/kg/day
Exclusion
- Severe comorbidity, including CHF, CVA, liver cirrhosis, COPD, Cushing's syndrome etc.
- Psychologic problems, including anxiety
- Incorporation, including personal and familial factors
Key Trial Info
Start Date :
October 1 2011
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2013
Estimated Enrollment :
51 Patients enrolled
Trial Details
Trial ID
NCT01473147
Start Date
October 1 2011
End Date
June 1 2013
Last Update
July 30 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Chang Gung Memorial Hospital
Taoyuan District, Taiwan, 333